In a filing, Travere Therapeutics Inc revealed its SENIOR VICE PRESIDENT, R&D ROTE WILLIAM E. unloaded Company’s shares for reported $0.12 million on Feb 12 ’25. In the deal valued at $23.53 per share,5,200 shares were sold. As a result of this transaction, ROTE WILLIAM E. now holds 98,519 shares worth roughly $ 2.26 million.
Then, REED ELIZABETH E sold 8,000 shares, generating $188,240 in total proceeds. Upon selling the shares at $23.53, the SVP, GC & CORPORATE SECRETARY now owns 89,482 shares.
Before that, Calvin Sandra sold 54,244 shares. Travere Therapeutics Inc shares valued at $1,356,100 were divested by the SVP, CHIEF ACCOUNTING OFFICER at a price of $25.00 per share. As a result of the transaction, Calvin Sandra now holds 54,410 shares, worth roughly $1.25 million.
Cantor Fitzgerald initiated its Travere Therapeutics Inc [TVTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late October from “an Equal weight” to “an Overweight”. Scotiabank began covering TVTX with “Sector outperform” recommendation on October 16, 2024. Guggenheim revised its rating on September 09, 2024. It rated TVTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TVTX
On Friday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock fall -3.41% to $22.91. Over the last five days, the stock has gained 5.33%. Travere Therapeutics Inc shares have risen nearly 31.52% since the year began. Nevertheless, the stocks have risen 186.73% over the past one year. While a 52-week high of $25.29 was reached on 02/11/25, a 52-week low of $5.12 was recorded on 01/14/25. SMA at 50 days reached $19.33, while 200 days put it at $13.49.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 22.44, which if violated will result in even more drops to 21.97. On the upside, there is a resistance level at 23.76. A further resistance level may holdings at 24.61. The Relative Strength Index (RSI) on the 14-day chart is 62.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.57, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 42.35%. Stochastics %K at 64.18% indicates the stock is a holding.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2025-01-31, growing by 0.84 million shares to a total of 9.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 8.72 million shares. There was a rise of 8.75%, which implies that there is a positive sentiment for the stock.
